Can effector cells be redirected to the site of the tumor?

Cancer Journal

Volumn 16, Issue 4, 2010, Pages 325-335

  Dubinett, Steven M ^a   Lee, Jay M ^b   Sharma, Sherven ^a   Mule, James J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antitumor immunity; Cancer vaccines; Chemokine receptors; Chemokines; Dendritic cells; Gene therapy; Immunotherapy; Infiltrating T cells

Indexed keywords

CCL1 CHEMOKINE; CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 100; INTERLEUKIN 2 RECEPTOR ALPHA; KEYHOLE LIMPET HEMOCYANIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MELAN A; MONOCYTE CHEMOTACTIC PROTEIN 1; NY ESO 1 ANTIGEN; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SECRETION; CELL STIMULATION; DENDRITIC CELL; DRUG EFFECT; DRUG SAFETY; HUMAN; LEUKOCYTE MIGRATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MELANOMA B16; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR IMMUNITY; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANIMALS; CHEMOKINES; HUMANS; NEOPLASMS; RECEPTORS, CHEMOKINE;

EID: 77957973787     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181eb33bc     Document Type: Review

References (64)

1. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol. 1995;6:86573.
2. Balkwill F. Cancer and the chemokine network. Nature Rev Cancer. 2004;4:540-550.
3. Yu P, Lee Y, Liu W, et al. Priming of naïve T cells inside tumors leads to eradication of established tumors. Nature Immunol. 2004;5:141-149.
4. Chen T, Guo J, Han C, et al. Heat shock protein 70, released from heatstressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182:1449-1459.
5. + T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol. 2008;181:8576-8584.
6. Yamazaki T, Yang XO, Chung Y, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181:8391-8401.
7. Brown CE, Vishwanath RP, Aguilar B, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol. 2007;179:3332-3341.
8. Gorbachev AV, Kobayashi H, Kudo D, et al. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol. 2007;178:2278-2286.
9. Shurin GV, Ferris RL, Tourkova IL, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005;174:5490-5498.
10. Zhang T, Somasundaram R, Berencsi K, et al. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol. 2005;174:5856-5863.
11. Pan J, Burdick MD, Belperio JA, et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol. 2006;176:1456-1464.
12. Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181:3099-3107.
13. Winter H, van den Engel NK, Rüttinger D, et al. Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. J Transl Med. 2007;5:56.
14. Ruffini PA, Morandi P, Cabioglu N, et al. Manipulating the chemokinechemokine receptor network to treat cancer. Cancer. 2007;109:2392-2404.
15. Mulé JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996;7:1545-1553.
16. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8:1021-1032.
17. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61:8513-8519.
18. Adema GJ, de Vries IJ, Punt CJ, et al. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol. 2005;17:170-174.
19. Verdijk P, Aarntzen EH, Punt CJ, et al. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther. 2008;8:865-874.
20. Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res. 2001;61:641-646.
21. Mullins DW, Engelhard VH. Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J Immunol. 2006;176:4535-4542.
22. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001;61:2062-2070.
23. Kirk CJ, Hartigan-O'Connor D, Mulé JJ. The dynamics of the T-cell antitumor response: chemokine secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 2001;61:8794-8802.
24. Terando A, Roessler B, Mulé JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther. 2004;11:165-173.
25. Kirk CJ, Mulé JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther. 2000;11:797806.
26. Yang SC, Batra RK, Hillinger S, et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006;66:3205-3213.
27. Sharma S, Stolina M, Luo J, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000;164:4558-4563.
28. Coppola D, Khalil F, Tjoelker L, et al. Ecotpic lymphoid tissue in colonic adenocarcinoma (abstract). In: Proceedings of the100th Annual Meeting of the American Association for Cancer Research, April 18-22, 2009, Denver, CO. Philadelphia, PA: AACR; 2009: abstract 9047.
29. Coppola D, Mulé JJ. Ectopic lymph nodes within human solid tumors. J Clin Oncol. 2008;26:4369-4370.
30. Coppola D, Nebozhyn M, Khalil F, et al. Ectopic lymph node-like structure presence and composition in colorectal carcinoma are predicted by immune gene array profiles: potential for cancer patient selection for vaccines and other immunotherapies. Proc Amer Soc Gene Cell Ther. In press.
31. Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res. 2004;10:2891-2901.
32. Ashour AE, Lin X, Wang X, et al. CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biol Ther. 2007;6:1206-1210.
33. Yousefieh N, Hahto S, Ciavarra RP. Gene therapy: CCL21 (SLC) inhibits primary prostate tumor growth and metastases. FASEB J. 2008;22:1076.15.
34. Novak L, Igoucheva O, Cho S, et al. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther. 2007;6:1755-1764.
35. Wu S, Xing W, Peng J, et al. Tumor transfected with CCL21 enhanced reactivity and apoptosis resistance of human monocyte derived dendritic cells. Immunobiology. 2008;213:417-426.
36. Thanarajasingam U, Sanz L, Diaz R, et al. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res. 2007;67:300-308.
37. Selvakumaran M, Biade S, Schick J, et al. Role of CCL19 and CCL21 chemokines in the response of ovarian tumors to platinum-based chemotherapy (abstract). Proc Amer Assoc Cancer Res. 2004;45: abstract 1472.
38. Shields JD, Kourtis IC, Tomei AA, et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010;328:749-752.
39. Riedl K, Baratelli F, Batra RK, et al. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer. 2003;2:35.
40. Sharma S, Miller PW, Stolina M, et al. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther. 1997;4:1361-1370.
41. Miller PW, Sharma S, Stolina M, et al. Dendritic cells augment granulocytemacrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther. 1998;5:380-389.
42. Sharma S, Yang SC, Batra RK, et al. Intratumoral therapy with cytokine gene-modified dendritic cells in murine lung cancer models. Methods Mol Med. 2003;75:711-722.
43. Dubinett SM, Patrone L, Tobias J, et al. Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo. Cancer Immunol Immunother. 1993;36:156-162.
44. Suh RD, Goldin JG, Wallace AB, et al. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment. Radiology. 2004;231:35964.
45. Gahery-Segard H, Molinier-Frenkel V, Le Boulaire C, et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest. 1997;100:2218-2226.
46. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985-991.
47. Miller PW, Sharma S, Stolina M, et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther. 2000;11:53-65.
48. Tatsumi T, Huang J, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003;63:6378-6386.
49. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755-1766.
50. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology. 1993;25:338-343.
51. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410-4417.
52. Kurabayashi A, Furihata M, Matsumoto M, et al. Distribution of tumorinfiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis. Pathol Int. 2004;54:302-310.
53. Lapteva N, Aldrich M, Rollins L, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009;17:1626-1636.
54. Lee JM, Garon EB, Baratelli F, et al. Phase I trial of CCL21 gene modified dendritic cells in non-small cell lung cancer. J Clin Oncol. 2010;28: abstract 51761.
55. + T-cell recruitment. Cancer Res. 2009;69:3077-3085.
56. Gajewski TF. Insights into mechanisms of immune resistance in the tumor microenvironment through molecular profiling. In: Yefenof E, ed. Innate and Adaptive Immunity in the Tumor Microenvironment. Vol. 1. Netherlands: Springer; 2008:77-89.
57. Lehmann F, Louahed J, Gaulis S, et al. Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment. Cancer Immunity. 2008;8(Suppl 2):27.
58. Louahed J, Gruselle O, Gaulis S, et al. Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol. 2008;26:9045.
59. Vansteenkiste JF, Zielinski M, Dahabreh IJ, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26:7501.
60. Pivarcsi A, Müller A, Hippe A, et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci USA. 2007;104:19055-19060.
61. Vianello F, Papeta N, Chen T, et al. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumorsepecific T cell chemorepulsion and escape from immune control. J Immunol. 2006;176:2902-2914.
62. Kershaw MH, Wang G, Westwood JA, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002;13:1971-1980.
63. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392-6402.
64. Liu Y-Q, Poon RT, Hughes J, et al. Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. World J Gastroenterol. 2005;11:164-170. (Pubitemid 40125197)